

# Camille Tlemsani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3996008/publications.pdf>

Version: 2024-02-01

44  
papers

1,010  
citations

567281

15  
h-index

434195

31  
g-index

50  
all docs

50  
docs citations

50  
times ranked

1947  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. <i>British Journal of Cancer</i> , 2013, 108, 1034-1041.	6.4	204
2	<i>CDH1</i> germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. <i>Journal of Medical Genetics</i> , 2013, 50, 486-489.	3.2	131
3	Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. <i>Targeted Oncology</i> , 2011, 6, 253-258.	3.6	117
4	SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. <i>Cell Reports</i> , 2020, 33, 108296.	6.4	86
5	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , 2020, 12, 473.	3.7	72
6	<i>SETD2</i> and <i>DNMT3A</i> screen in the Sotos-like syndrome French cohort. <i>Journal of Medical Genetics</i> , 2016, 53, 743-751.	3.2	54
7	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	35
8	Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 785-794.	3.3	31
9	High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1232-1239.	1.1	29
10	Hereditary diffuse gastric cancer syndrome: improved performances of the 2015 testing criteria for the identification of probands with a <i>CDH1</i> germline mutation. <i>Journal of Medical Genetics</i> , 2015, 52, 563-565.	3.2	22
11	Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with <i>de novo</i> carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 886-896.	5.1	22
12	Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 45-53.	2.3	20
13	Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. <i>Investigational New Drugs</i> , 2017, 35, 242-246.	2.6	20
14	Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1433-1444.	3.3	19
15	Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. <i>Clinical Nutrition</i> , 2020, 39, 1893-1899.	5.0	16
16	Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers. <i>Chest</i> , 2020, 158, 1723-1733.	0.8	16
17	Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial. <i>Thyroid</i> , 2019, 29, 1820-1827.	4.5	15
18	<i>NF1</i> mutations identify molecular and clinical subtypes of lung adenocarcinomas. <i>Cancer Medicine</i> , 2019, 8, 4330-4337.	2.8	14

#	ARTICLE	IF	CITATIONS
19	Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. <i>Clinical Therapeutics</i> , 2020, 42, 1302-1316.	2.5	13
20	First referral to an integrated onco-palliative care program: a retrospective analysis of its timing. <i>BMC Palliative Care</i> , 2020, 19, 31.	1.8	11
21	Integration of Oncology and Palliative Care, a Forgotten Indicator: Shared Decision-Making. <i>Oncologist</i> , 2015, 20, e26.	3.7	9
22	Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 673-687.	4.1	7
23	Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. <i>European Journal of Cancer</i> , 2016, 66, 75-82.	2.8	5
24	BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine. <i>American Journal of the Medical Sciences</i> , 2018, 356, 404-407.	1.1	5
25	One NF1 Mutation may Conceal Another. <i>Genes</i> , 2019, 10, 633.	2.4	5
26	Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung Cancer. <i>Annals of Nutrition and Metabolism</i> , 2019, 75, 223-230.	1.9	4
27	Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 741-751.	2.3	4
28	No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks Outcome?. <i>Cancers</i> , 2022, 14, 2620.	3.7	4
29	Acquired Type II von Willebrand Syndrome in Locally Advanced Bladder Cancer Successfully Treated With Intravenous Immunoglobulin and Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e95-e97.	1.9	3
30	Individualized Pazopanib Dosing Letter. <i>Clinical Cancer Research</i> , 2017, 23, 6377-6377.	7.0	3
31	Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients. <i>Pharmaceutics</i> , 2022, 14, 1224.	4.5	3
32	Vinorelbine-based chemotherapy in metastatic epithelioid sarcoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e22549-e22549.	1.6	2
33	Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris. <i>Clinical Medicine</i> , 2021, 21, e552-e555.	1.9	1
34	Abstract P3-10-03: Receipt of breast cancer risk assessment and personalized prevention information among women diagnosed with a benign breast lesion (BBL) in a one stop breast unit: A prospective assessment. , 2016, , .		1
35	Evaluation of baseline asymptomatic dysimmunity prevalence in cancer patients receiving monoclonal anti-PD1 antibodies.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14551-e14551.	1.6	1
36	Identification of patients at risk for severe toxicity under PD1 inhibitors: role of sarcopenic overweight. <i>Annals of Oncology</i> , 2016, 27, vi373.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Abstract P5-15-12: Clinico-biological characteristics of patients surviving more than two years with metastatic breast cancer (MBC): Results of a transversal national multicentric survey. , 2015, , .		0
38	Is standard dose appropriate in elderly non-small cell lung carcinoma (NSCLC) patients treated with erlotinib?. Journal of Clinical Oncology, 2015, 33, 9537-9537.	1.6	0
39	Identification of candidates for sorafenib dose-escalation using sorafenib plasmatic concentration monitoring: Proof of concept.. Journal of Clinical Oncology, 2015, 33, 2572-2572.	1.6	0
40	A multidisciplinary team dedicated to the management of patients treated with PD1 inhibitors: The Cochon hospital experience.. Journal of Clinical Oncology, 2016, 34, e18208-e18208.	1.6	0
41	Relationship between sarcopenia and dose-limiting toxicity (DLT) of sorafenib (SOR) in patients (pts) with advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) in the phase III DECISION trial.. Journal of Clinical Oncology, 2017, 35, e17594-e17594.	1.6	0
42	Association of muscle mass with pathologic response and toxicity in localized bladder cancer patients treated by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC).. Journal of Clinical Oncology, 2017, 35, e16022-e16022.	1.6	0
43	Specific needs of non-visceral sarcoma patients: Evidence from an early multidisciplinary intervention.. Journal of Clinical Oncology, 2018, 36, e22133-e22133.	1.6	0
44	Metabolic profile and neoadjuvant chemotherapy sensitivity in high-grade bone sarcoma.. Journal of Clinical Oncology, 2019, 37, e22506-e22506.	1.6	0